ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

SNPX Synaptogenix Inc

4.9999
0.5479 (12.31%)
Last Updated: 13:33:24
Delayed by 15 minutes

Period:

Draw Mode:

Volume 125,887
Bid Price 4.84
Ask Price 5.00
News -
Day High 5.12

Low
3.5275

52 Week Range

High
47.00

Day Low 4.35
Share Name Share Symbol Market Stock Type
Synaptogenix Inc SNPX NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.5479 12.31% 4.9999 13:33:24
Open Price Low Price High Price Close Price Previous Close
4.44 4.35 5.12 4.452
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
728 125,887 US$ 4.73 US$ 594,871 - 3.5275 - 47.00
Last Trade Type Quantity Price Currency
13:33:58 34 US$ 4.92 USD

Synaptogenix Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
97.47M 20.39M - 0 -13.78M -0.68 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Synaptogenix News

Date Time Source News Article
4/24/202408:15PR Newswire (US)Synaptogenix Regains Compliance with Nasdaq Minimum Bid..
4/09/202408:15PR Newswire (US)Synaptogenix Increases Stake in Innovative Psilocybin Drug..
4/03/202407:00PR Newswire (US)Synaptogenix Announces Reverse Stock Split to Maintain..
2/06/202409:16Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial..
12/21/202316:00Edgar (US Regulatory)Form 8-K - Current report
12/19/202308:00PR Newswire (US)Synaptogenix President Daniel L. Alkon, M.D. Honored for..
12/06/202308:00PR Newswire (US)Synaptogenix Joins Leading Neuroscientists and Academics as..
11/14/202316:05Edgar (US Regulatory)Form ARS - Annual Report to Security Holders
11/13/202316:00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statements
11/06/202316:00Edgar (US Regulatory)Form 8-K - Current report
11/03/202316:00Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statements
11/02/202308:00PR Newswire (US)Synaptogenix Acquires Significant Stake in Cannasoul..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No SNPX Message Board. Create One! See More Posts on SNPX Message Board See More Message Board Posts

Historical SNPX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week4.435.124.344.5317,4010.569912.86%
1 Month4.726.2173.8654.63221,7500.27995.93%
3 Months5.08257.22253.52755.25555,180-0.0826-1.63%
6 Months6.508.7753.52755.54554,268-1.50-23.08%
1 Year22.5047.003.527511.93660,550-17.50-77.78%
3 Years187.50362.503.527578.86348,821-182.50-97.33%
5 Years187.50362.503.527578.86348,821-182.50-97.33%

Synaptogenix Description

Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.

Your Recent History

Delayed Upgrade Clock